Open-label Study of Inhaled RVT-1601 in Preterm Infants

Open-label Study to Assess the Safety, Tolerability, Feasibility, and Pharmacokinetics of Inhaled RVT-1601 in Preterm Infants at High-risk for Long-term Respiratory Morbidities

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04007120

Enrollment

Registered

2019-07-05

Start date

2019-10-01

Completion date

2020-05-29

Last updated

2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Morbidities of Prematurity (RMP)

Brief summary

Preterm birth predisposes infants to greater risk for respiratory morbidities and the need for pulmonary care compared to term infants both in the short-term and long-term. In the short-term, preterm birth is a high risk factor for development of bronchopulmonary dysplasia (BPD), the second most common chronic pediatric respiratory disease after asthma. In the long-term, following discharge from the neonatal intensive care unit (NICU) and the hospital, preterm birth carries a high risk for respiratory morbidities (e.g., wheezing, cough, doctor visits, and hospitalizations for respiratory infections) and resource use, which in turn predisposes infants to the development of lung diseases in childhood and adulthood, including airway hyperresponsiveness, asthma, and chronic obstructive pulmonary disease (COPD). There is a significant unmet need for safe and efficacious approaches in the prevention and treatment of respiratory morbidities of prematurity. The study will be conducted in the neonatal intensive care unit (NICU) in preterm infants to determine safety, tolerability and lung delivery performance of RVT-1601, a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer/face mask.

Interventions

DRUGRVT-1601

Inhaled RVT-1601 administered once daily over two days

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

32 Months to 35 Months

Healthy volunteers

Inclusion criteria

* Preterm infants between 32 weeks 0 days and 34 weeks 6 days of PMA * Born between 24 weeks 0 days and 29 weeks 6 days of estimated GA * Requiring minimal or no respiratory support (i.e., supplemental oxygen with \<2 liters per minute of nasal cannula flow acceptable) * Body weight appropriate for gestational age * Written informed consent obtained from at least one of the parents or legal guardians

Exclusion criteria

* Requiring invasive or noninvasive respiratory support (e.g., mechanical ventilation, CPAP) * Clinically unstable (i.e. unable to maintain SpO2 between 90-95 % , escalating respiratory support in the past 24 hours) * Major congenital anomaly (chromosomal, renal, cardiac, hepatic, neurologic or pulmonary malformations) * Significant cardiac disorder (i.e., pulmonary hypertension) * History of major surgical procedure * Any condition that would preclude receiving study drug or performing any study-related procedures * Participation in any other investigational drug study * History of hypersensitivity or intolerance to cromolyn sodium

Design outcomes

Primary

Measure	Time frame	Description
Change in heart rate	Pre-dose and 15 minutes post-dose	Assessment of heart rate (beats/min)
Change in blood pressure	Pre-dose and 15 minutes post-dose	Assessment of systolic and diastolic blood pressure (mmHg)
Change in oxygenation	Pre-dose and 15 minutes post-dose	Assessment of peripheral capillary oxygen saturation (SpO2)

Secondary

Measure	Time frame	Description
Peak plasma concentration (Cmax)	30 minutes post-dose	Assessment of peak plasma concentration of RVT-1601
Total urine excretion	8 hours post-dose	Assessment of total urine content of RVT-1601

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026